Direxion Daily Healthcare Bull 3X ETF
CURE
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Leveraged
- Address
- 1301 Avenue of the Americas, 28th Floor New York NY United States of America 10019
- IPO Date
- Jun 15, 2011
- CIK
- 0001424958
- Website
- direxion.com
- Similar Companies
- Business
- Direxion Daily Healthcare Bull 3X Shares (CURE) is an exchange-traded fund that provides leveraged investment results, on a daily basis, corresponding to three times (3x) the daily performance of the ICE BofA US Health Care Select Sector Index, net of fees and expenses. The fund employs swap agreements, futures contracts, options, and exchange-traded funds to achieve its leveraged exposure to the healthcare sector, which includes biotechnology, pharmaceuticals, healthcare providers, health services, and medical devices; it does not invest directly in the underlying index constituents. CURE targets sophisticated investors seeking amplified short-term returns from healthcare market movements and operates primarily in the United States, listed on the NYSE Arca exchange. Direxion Shares ETF Trust, the issuer founded in 1997 and headquartered in Rye Brook, New York, manages CURE as part of its suite of leveraged and inverse ETFs across sectors including technology, energy, and financials. The fund's assets under management fluctuate with market conditions, serving institutional and retail traders focused on tactical, high-volatility strategies rather than long-term buy-and-hold investing. Geographically, it focuses on U.S.-listed healthcare equities, with no direct international operations. In recent developments, Direxion announced enhancements to its leveraged ETF lineup in 2024, including improved liquidity provisions and expanded share classes for select funds amid rising demand for sector-specific leverage amid healthcare sector volatility driven by biotech innovations and policy shifts. The firm also partnered with Rafferty Asset Management to optimize swap counterparty arrangements, reducing operational costs for funds like CURE. No major acquisitions, rebrands, or structural changes have occurred for CURE specifically within the last two years, though Direxion continues to monitor regulatory updates from the SEC on leveraged ETF disclosures.